MedPath

Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression

Recruiting
Conditions
Glaucoma
Registration Number
NCT05801471
Lead Sponsor
Centervue SpA
Brief Summary

The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Glaucomatous optic nerve head in both eyes;
  • Age between 40 and 90 years;
  • Best Corrected Visual Acuity ≤ 0.3 [logMar];
  • Spherical refraction between -6D and +6D;
  • Astigmatism between -2D and +2D.
Exclusion Criteria
  • Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment;
  • Any ocular pathology that can affect visual field other than glaucoma;
  • Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss;
  • Inability to obtain reliable perimetric examinations;
  • Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).1 visit every 4 months (10 visits total), up to 3 years

Equivalence will be defined as the 95% confidence Intervals of the mean difference between the slopes estimated with the two devices being within ± 0.1 dB/year

Secondary Outcome Measures
NameTimeMethod
Quantification of the effect of the integration of the rate of progression of structural metrics into the calculation of the rate of progression of the MD1 visit every 4 months (10 visits total), up to 3 years

Quantification of the effect of the integration of the rate of progression of structural metrics (mainly the retinal nerve fiber layer thickness, microns/year) into the calculation of the rate of progression of the MD. This effect will be quantified as the improvement in the equivalence metric defined for Outcome 1

The integration of structural OCT RNFL thickness information into progression analysis will be done using a Bayesian Linear Regression approach as suggested by Russel at al.\[\*\]

\[\*\] R.A. Russel at al.; "Improved Estimates of Visual Field Progression Using Bayesian Linear Regression to Integrate Structural Information in Patients with Ocular Hypertension"; IOVS May 2012; 53(6): 2760-2769.

Difference in time to identify progression between Compass and HFA using an event analysis1 visit every 4 months (10 visits total), up to 3 years

Time of first detectable change \[years\]

Trial Locations

Locations (2)

Glaucoma Research Center, IRCCS Fondazione "G.B. Bietti"

🇮🇹

Roma, Italy

Clinica oculistica Ospedale San Paolo

🇮🇹

Milano, Italy

© Copyright 2025. All Rights Reserved by MedPath